2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
April 2026 in “The Journal of Dermatology” Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
May 2025 in “International Journal of Trichology” Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
20 citations
,
October 2024 in “British Journal of Dermatology” The guideline provides recommendations for managing alopecia areata effectively.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
January 2026 in “Dermatologica Sinica” New and repurposed treatments are improving outcomes in dermatology.
July 2025 in “Skin Appendage Disorders” Improving education, insurance, and support can help scarring alopecia patients access better care.